Industry

ASPC News Community Community : Women in PC Industry Patient Care and Advocacy

PRALUENT® (ALIROCUMAB) INJECTION RECEIVES FDA APPROVAL TO TREAT CHILDREN WITH GENETIC FORM OF HIGH C
PRALUENT® (ALIROCUMAB) INJECTION RECEIVES FDA APPROVAL TO TREAT CHILDREN WITH GENETIC FORM OF HIGH C

TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent® (alirocumab) as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C) lowering... Continue Reading

Date posted03/11/2024


Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease a
Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease a

PLAINSBORO, N.J., March 8, 2024 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Wegovy® to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart... Continue Reading

Date posted03/8/2024